newsfilter
← Latest News
Business Wire·

Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Completed $25 million registered direct stock offering priced at the market Initiated Phase 2a Long COVID clinical trial Fast Track designation received from FDA for AXA1125 in NASH with liver fibrosis Enhanced management team Long COV